Notice2023-01418
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 25, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 16 (Wednesday, January 25, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 16 (Wednesday, January 25, 2023)]
[Notices]
[Pages 4833-4834]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-01418]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Amy F. Petrik, Ph.D., 240-627-3721;
<a href="/cdn-cgi/l/email-protection#13727e6a3d637667617a78537d7a7b3d747c65"><span class="__cf_email__" data-cfemail="fc9d9185d28c99888e9597bc929594d29b938a">[email protected]</span></a>. Licensing information and copies of the U.S. patent
application listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows: Antibodies
with potent and broad neutralizing activity against antigenically
diverse and highly transmissible SARS-CoV-2 variants.
Description of Technology:
Emergence of highly transmissible SARS-CoV-2 variants of concern
that are resistant to current therapeutic antibodies highlights the
need for continuing discovery of broadly reactive antibodies.
Scientists at the Vaccine Research Center of the National Institute
of Allergy and Infectious Diseases have engineered a group of human
monoclonal antibodies that target epitopes on the receptor binding
domain of SARS-CoV-2 spike protein.
[[Page 4834]]
These engineered antibodies ultra-potently neutralize >12 variants of
SARS-CoV-2, including the highly transmissible BA.4 and BA.5
subvariants of Omicron, as shown in a pseudovirus neutralization assay.
These engineered antibodies target 3 distinct epitopes in the receptor
binding domain of the spike protein and function by blocking ACE2
binding. These engineered antibodies are not impacted by spike
mutations that knockout binding to other therapeutic antibodies,
including E484K, N439K, Y453F, L452R and K417N. Several of the
engineered antibodies are able to simultaneously bind to the spike
protein and are compatible for use in combination therapies. In in
vitro assays, these combinations were shown to decrease the appearance
of escape mutants suggesting the potential to mitigate resistance
development when used as combination therapy. Additionally, these
engineered antibodies are better suited for manufacturing than the
parental antibodies.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications:
<bullet> Treatment of SARS-CoV-2 infection
Competitive Advantages:
<bullet> Ultra-potent neutralization of currently identified SARS-CoV-2
variants including Omicron subvariants
<bullet> Combinations show the potential to mitigate resistance
<bullet> Improved manufacturability relative to parental antibodies
<bullet> Mechanism of Action--These antibodies bind to block ACE2
receptor binding to the SARS CoV-2 spike protein
Development Stage: Preclinical Research.
Inventors: John Misasi (VRC, NIAID), Lingshu Wang (VRC, NIAID),
John Mascola (VRC, NIAID), Nancy Sullivan (VRC, NIAID), Misook Choe
(VRC, NIAID), Richard Alan Koup (VRC, NIAID), Man Chen, (VRC, NIAID),
Tongqing Zhou (VRC, NIAID), Peter Kwong (VRC, NIAID), Wei Shi (VRC,
NIAID), Yi Zhang (VRC, NIAID), Eun Sung Yang (VRC, NIAID).
Publications: None.
Intellectual Property: HHS Reference Number E-185-2022 includes
U.S. Provisional Patent Application Number 63/404,473 filed September
7, 2022.
Licensing Contact: To license this technology, please contact Amy
F. Petrik, Ph.D., 240-627-3721; <a href="/cdn-cgi/l/email-protection#3d5c5044134d58494f54567d535455135a524b"><span class="__cf_email__" data-cfemail="bddcd0c493cdd8c9cfd4d6fdd3d4d593dad2cb">[email protected]</span></a>.
Dated: January 19, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-01418 Filed 1-24-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 25, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.